Updated Approaches Against SARS-CoV-2

Antimicrob Agents Chemother. 2020 May 21;64(6):e00483-20. doi: 10.1128/AAC.00483-20. Print 2020 May 21.

Abstract

Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lies behind the ongoing outbreak of coronavirus disease 2019 (COVID-19). There is a growing understanding of SARS-CoV-2 in virology, epidemiology, and clinical management strategies. However, no anti-SARS-CoV-2 drug or vaccine has been officially approved due to the absence of adequate evidence. Scientists are racing to develop a treatment for COVID-19. Recent studies have revealed many attractive therapeutic options, even if some of them remain to be further confirmed in rigorous preclinical models and clinical trials. In this minireview, we aim to summarize the updated potential approaches against SARS-CoV-2. We emphasize that further efforts are warranted to develop the safest and most effective approach.

Keywords: COVID-19; SARS-CoV-2; antiviral drugs; treatment; vaccines.

Publication types

  • Review

MeSH terms

  • Betacoronavirus*
  • Coronavirus Infections / immunology
  • Coronavirus Infections / prevention & control
  • Coronavirus Infections / therapy*
  • Humans
  • Inflammation / prevention & control
  • Medicine, Chinese Traditional
  • Pandemics / prevention & control
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / prevention & control
  • Pneumonia, Viral / therapy*
  • Virus Internalization
  • Virus Replication

Supplementary concepts

  • COVID-19
  • severe acute respiratory syndrome coronavirus 2